Zacks Investment Research
05 Aug 2026, 00:31 UTC · 1h ago
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 00:31 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ultragenyx (RARE) reported Q2 2026 revenue of $214 million, exceeding the Zacks Consensus Estimate of $181.01 million by 18.23%. — A significant revenue beat typically signals stronger-than-expected commercial traction and positive momentum for the stock.
+0.40Ultragenyx delivered an EPS of -$0.90, beating the consensus estimate of -$1.27 by 29.13%. — Beating earnings expectations, even while remaining unprofitable, indicates better cost management or operational efficiency than analysts projected.
+0.30Ultragenyx's quarterly revenue increased 28.5% year-over-year. — Steady double-digit top-line growth supports the long-term growth thesis for a biotech company.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company reported a revenue surprise of 18.23% and an EPS surprise of 29.13%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
